These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 25891230)

  • 21. Seroprevalence of HCV and HIV infection among clients of the nation's longest-standing statewide syringe exchange program: A cross-sectional study of Community Health Outreach Work to Prevent AIDS (CHOW).
    Salek TP; Katz AR; Lenze SM; Lusk HM; Li D; Des Jarlais DC
    Int J Drug Policy; 2017 Oct; 48():34-43. PubMed ID: 28779632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance.
    Rosińska M; Sierosławski J; Wiessing L
    BMC Infect Dis; 2015 Feb; 15():83. PubMed ID: 25879904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
    Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
    Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlates of anti-hepatitis C positivity and use of harm reduction services among people who inject drugs in two cities in Croatia.
    Handanagic S; Sevic S; Barbaric J; Dominkovic Z; Dakovic Rode O; Begovac J; Bozicevic I
    Drug Alcohol Depend; 2017 Feb; 171():132-139. PubMed ID: 28088084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C Virus seroconversion among persons who inject drugs in relation to primary care physician visiting: The potential role of primary healthcare in a combined approach to Hepatitis C prevention.
    Artenie AA; Roy É; Zang G; Jutras-Aswad D; Bamvita JM; Puzhko S; Daniel M; Bruneau J
    Int J Drug Policy; 2015 Oct; 26(10):970-5. PubMed ID: 26005038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription opiate analgesics, heroin, HIV and HCV among persons who inject drugs in New York City, 2016-2018.
    Des Jarlais DC; Arasteh K; McKnight C; Feelemyer J; Perlman DC; Tross S
    Drug Alcohol Depend; 2019 Nov; 204():107459. PubMed ID: 31521951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Trends in sources and sharing of needles among people who inject drugs, San Francisco, 2005-2012.
    Kim NJ; Jin H; McFarland W; Raymond HF
    Int J Drug Policy; 2015 Dec; 26(12):1238-43. PubMed ID: 26365768
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High prevalence of hepatitis C virus infection and low level of awareness among people who recently started injecting drugs in a cross-sectional study in Germany, 2011-2014: missed opportunities for hepatitis C testing.
    Enkelmann J; Gassowski M; Nielsen S; Wenz B; Roß S; Marcus U; Bremer V; Zimmermann R;
    Harm Reduct J; 2020 Jan; 17(1):7. PubMed ID: 31924208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.
    Eckhardt B; Winkelstein ER; Shu MA; Carden MR; McKnight C; Des Jarlais DC; Glesby MJ; Marks K; Edlin BR
    PLoS One; 2017; 12(5):e0177341. PubMed ID: 28542351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011.
    Iversen J; Grebely J; Topp L; Wand H; Dore G; Maher L
    J Viral Hepat; 2014 Mar; 21(3):198-207. PubMed ID: 24438681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs.
    Doyle M; Maher L; Graham S; Wand H; Iversen J
    Aust N Z J Public Health; 2018 Feb; 42(1):52-56. PubMed ID: 29168317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An assessment of an HIV prevention intervention among people who inject drugs in the states of Manipur and Nagaland, India.
    Goswami P; Medhi GK; Armstrong G; Setia MS; Mathew S; Thongamba G; Ramakrishnan L; George B; Singh RK; Paranjape RS; Mahanta J
    Int J Drug Policy; 2014 Sep; 25(5):853-64. PubMed ID: 24925819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence of hepatitis C virus infection among injecting drug users in Glasgow 1990-1996: are current harm reduction strategies working?
    Taylor A; Goldberg D; Hutchinson S; Cameron S; Gore SM; McMenamin J; Green S; Pithie A; Fox R
    J Infect; 2000 Mar; 40(2):176-83. PubMed ID: 10841096
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C transmission and treatment as prevention - The role of the injecting network.
    Hellard M; McBryde E; Sacks Davis R; Rolls DA; Higgs P; Aitken C; Thompson A; Doyle J; Pattison P; Robins G
    Int J Drug Policy; 2015 Oct; 26(10):958-62. PubMed ID: 26072105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Geographic Differences in Temporal Incidence Trends of Hepatitis C Virus Infection Among People Who Inject Drugs: The InC3 Collaboration.
    Morris MD; Shiboski S; Bruneau J; Hahn JA; Hellard M; Prins M; Cox AL; Dore G; Grebely J; Kim AY; Lauer GM; Lloyd A; Rice T; Shoukry N; Maher L; Page K;
    Clin Infect Dis; 2017 Apr; 64(7):860-869. PubMed ID: 28362947
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Undiagnosed HIV and Hepatitis C infection in people who inject drugs: From new evidence to better practice.
    Parés-Badell O; Espelt A; Folch C; Majó X; González V; Casabona J; Brugal MT
    J Subst Abuse Treat; 2017 Jun; 77():13-20. PubMed ID: 28476265
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in hepatitis C virus prevalence and incidence among people who inject drugs in the direct acting antiviral era.
    Gahrton C; Navér G; Warnqvist A; Dalgard O; Aleman S; Kåberg M
    Int J Drug Policy; 2024 Jun; 128():104433. PubMed ID: 38703622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.